News
The GABA excitatory/inhibitory shift in brain maturation and neurological disorders
Ionic currents and the network-driven patterns they generate differ in immature and adult neurons: The developing brain is not a “small adult brain.” One of the most investigated examples is the developmentally regulated shift of actions of the transmitter GABA that inhibit adult neurons but excite immature ones because of an initially higher intracellular chloride concentration [Cl(-)](i), leading to depolarizing and often excitatory actions of GABA instead of hyperpolarizing and inhibitory actions. The levels of [Cl(-)](i) are also highly labile, being readily altered transiently or persistently by enhanced episodes of activity in relation to synaptic plasticity or a variety of pathological conditions, including seizures and brain insults. Among the plethora of channels, transporters, and other devices involved in controlling [Cl(-)](i), two have emerged as playing a particularly important role: the chloride importer NKCC1 and the chloride exporter KCC2. Here, the authors stress the importance of determining how [Cl(-)](i) is dynamically regulated and how this affects brain operation in health and disease. In a clinical perspective, agents that control [Cl(-)](i) and reinstate inhibitory actions of GABA open novel therapeutic perspectives in many neurological disorders, including infantile epilepsies, autism spectrum disorders, and other developmental disorders.
Yehezkel Ben-Ari 1 , Ilgam Khalilov, Kristopher T Kahle, Enrico Cherubini
Scientific papers
- Smaller brain volumes after birth by Cesarean Section 24 March 2021
- The GABA developmental sequence is altered in a mouse model of Rett Syndrome 26 June 2019
- No stop-growing signal around birth in a rodent model of autism 24 January 2019
- Immune activation during gestation leads to hippocampal neuronal alterations already at birth 4 November 2018
- A promising multicenter trial to alleviate autistic disorders 14 March 2017
- The diuretic Bumetanide and the birth hormone Oxytocin point to a common pathway in the early pathogenesis of Autism in rodents 26 February 2014
- Treating Fragile X syndrome with the diuretic bumetanide: a case report 10 June 2013
- A randomised controlled trial of bumetanide in the treatment of autism in children 11 December 2012
- The GABA excitatory/inhibitory shift in brain maturation and neurological disorders 18 October 2012